Cashu
CytomX Therapeutics Faces Mixed Analyst Ratings Amid Clinical Developments and Market Competition
4 days ago
Stocks
Health Care
ctmx
CytomX Therapeutics
NASDAQ: CTMX
+2.17 (+46.37%)
6.85
USD
At close at Mar 16, 19:40 UTC
Overview
Loading chart...
Key Stats
Market Cap
771.79M
Dividend Yield
0.00%
P/E Ratio
27.55
EPS
0.39
Revenue
138.10M
Avg. Volume
3.20M
About
What does CTMX do?
CytomX Therapeutics, a clinical-stage biopharmaceutical company based in South San Francisco, develops conditionally activated biologics for oncology, with a pipeline including CX-904 and CX-2051. The company went public on October 8, 2015, and has 120 employees.
Join our newsletter to keep up to date with us!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.